Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-Week results of a randomized trial
2017
Objectives
Primary study outcome was absence of treatment failure (virological failure, VF, or treatment interruption) per protocol at week 48.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
30
References
19
Citations
NaN
KQI